US WorldMeds
US WorldMeds is a privately held specialty pharmaceutical company that develops, licenses, and markets medicines for patients with rare and challenging conditions.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs. It describes itself as a sustainable, privately held specialty pharmaceutical company focused on licensing, developing, and delivering medicines for patients with rare and challenging conditions, with stated areas of focus including hematology and oncology. Its product portfolio includes IWILFIN, Revonto, Tecelra, and, through Hema Biologics, Sevenfact. The company is based in Louisville, United States.
History
US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs. The company states that it is committed to developing medications in hematology and oncology, and describes itself as a sustainable, privately held specialty pharmaceutical company whose mission is to develop, license, and market meaningful and accessible healthcare products. Its stated areas of focus include high-risk neuroblastoma, malignant hyperthermia, and synovial sarcoma. Its product portfolio includes IWILFIN, Revonto, and Tecelra, and it is associated with Hema Biologics and Sevenfact. The company is based in Louisville, United States.
Products and positioning
Specialty pharmaceuticals with a personal touch—improving lives by licensing, developing, and delivering medicines for patients with rare and challenging conditions.
IWILFIN
A product listed in the US WorldMeds portfolio; IWILFIN is a registered trademark of USWM, LLC.
Revonto
A product listed in the US WorldMeds portfolio; Revonto is a registered trademark of USWM, LLC.
Tecelra
A product listed in the US WorldMeds portfolio; Tecelra is a registered trademark of USWM CT, LLC.
Sevenfact
A product listed in the US WorldMeds portfolio; SEVENFACT is a registered trademark of LFB S.A., and HEMA Biologics, LLC is the exclusive licensee and distributor of SEVENFACT in the United States and its territories.
Recent events
US WorldMeds acquires Orbus Therapeutics[6]
Reported:
US WorldMeds acquired Orbus Therapeutics, adding Orbus' late-stage eflornithine program for recurrent Grade 3 astrocytoma to its rare-disease portfolio. Orbus became a wholly owned subsidiary of US WorldMeds.
US WorldMeds announces partnership to provide LUCEMYRA to patients in need[7]
Reported:
US WorldMeds announced a partnership with FEMA and Healthcare Ready and, with FEMA and its partnership with Healthcare Ready, is donating approximately $500,000 worth of LUCEMYRA to VIP Community Services in the Bronx for eligible patients facing unplanned opioid withdrawal to access at no charge.
Sources7 sources
- 1US WorldMeds | Pharmaceutical Manufacturerusworldmeds.com
- 2About Us | US WorldMedsusworldmeds.com
- 3Products | Medications | US WorldMedsusworldmeds.com
- 4Research & Development | US WorldMedsusworldmeds.com
- 5US WorldMeds (United States)wikidata.org
- 6US WorldMeds 收购 Orbus Therapeuticsprnewswire.com
- 7US WorldMeds宣布合作向有需要的患者提供LUCEMYRAprnewswire.com
Cite this profile: Cite the canonical profile. /brand-wiki/us-worldmeds-united-states · Editorial policy · How profiles are compiled